Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexicon Pharmaceuticals, Inc. - Common Stock (NQ:LXRX)

0.9010 -0.0149 (-1.63%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lexicon Pharmaceuticals, Inc. - Common Stock

Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)
Oral presentation on study demonstrating the ability of sotagliflozin to reduce the risk of hypoglycemic events regardless of kidney function in people with type 1 diabetes 
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Emerging Tech Quartet – PRSO, LXRX, PRTG, RNAZ – Drive Breakthroughs Across Defense, Obesity, Oncology, and RNA Therapeutics
Via AB Newswire
Topics Intellectual Property
Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain
Event will feature insights on LX9211, Lexicon’s novel, investigational, non-opioid treatment, as well as expert panel and Q&A session on DPNP 
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon Appoints Scott Coiante as Chief Financial Officer
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
Confirms Previously Disclosed and Anticipated FDA Decision 
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon Pharmaceuticals to Participate in December Investor Conferences
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon Appoints Ivan H. Cheung to Board of Directors
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Global Diabetes Care Market Size Expected To Reach $41.71 Billion By 2027
EQNX::TICKER_START (OTCPK:CNER),(NYSE:NVO),(NASDAQ:TNDM),(NASDAQ:DXCM),(NASDAQ:LXRX) EQNX::TICKER_END 
Via FinancialNewsMedia
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Investor Notice: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 05/09/2022 -- Certain directors of Lexicon Pharmaceuticals, Inc are under investigation over potential breaches of fiduciary duties. 
Via SBWire
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Investor Notice: Investigation over Potential Securities Laws Violations
San Diego, CA -- (SBWIRE) -- 03/24/2022 -- An investigation was announced over possible violations of securities laws by Lexicon Pharmaceuticals, Inc. 
Via SBWire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.